Acifran is a clinically-used drug that primarily targets both HCAR2 (EC50 = 10−5.7M) and HCAR3 (EC50 = 10−4.7M), to treat hypertriglyceridemia, type 2 diabetes, and metabolic syndrome [18,19]. This evidence concerns the gene HCAR2 and metabolic syndrome.